Latest Conference Articles

These late-breaking data presented at RAD 2025 highlight dupilumab’s efficacy and safety in this often neglected patient population.

A deep dive into several noteworthy IgAN studies presented during the ERA 2025 Congress.

A RaDaR analysis from ERA 2025 provides insight into predictors of disease progression, outcomes in patients with Alport syndrome.

These phase 3b findings highlight lebrikizumab’s efficacy and safety in adult and adolescent patients with skin of color living with atopic dermatitis.

Most modern GDMT components were prescribed to less than half of all patients included in the EMPACE study, indicating the need for strategies to enhance clinical adoption.

This interview features a discussion with Lio regarding pediatric atopic dermatitis and the connection between caregivers, patients, and providers.

Michos discusses framing obesity as hyperandrogenism, with reductions in estrogen production contributing to higher visceral adiposity.

Discover groundbreaking insights on the VISIONARY trial, IgA nephropathy treatment, and the future of kidney care with expert Vlado Perkovic, MBBS, PhD.

Study findings highlight the potential utility of cardiac catheterization as a targeted intervention in pre-kidney transplant cardiac risk stratification.

Pagidipati describes barriers to implementing guideline-directed medical therapy in patients with cardiometabolic diseases and steps needed to overcome them.

Khan’s presentation indicates that combination screening is the optimal method of identifying heart failure risk while minimizing the percentage of cases missed.

A study presented at ERA 2025 validates the use of proteinuria as a surrogate endpoint for FSGS clinical trials.

This interview highlights 3 new topical non-steroidal options for atopic dermatitis covered in Kircik’s RAD 2025 presentation on FDA approvals.

An ERA 2025 analysis confirms empagliflozin significantly lowers acute kidney injury risk, reassuring clinicians about its safety in at-risk patients.

In this interview with Shahriari at RAD 2025, she highlights some of the most significant burdens that patients and caregivers face with atopic dermatitis.

Investigators compared the efficacy of tirzepatide and liraglutide in lowering rates of all-cause mortality in patients with obesity and sleep apnea.

In this Q&A interview, Silverberg highlighted takeaways from his talk at RAD 2025 on recent FDA approvals for atopic dermatitis.

52-week data from the VALIANT program shed further light on the potential of pegcetacoplan in C3G and IC-MPGN.

Prespecified analysis of 320 patients in VISIONARY were presented at ERA 2025 Congress.

In this session at RAD 2025, Tiffany Mayo, MD, spoke to attendees about several examples of complex cases in atopic dermatitis and touched on hair loss concerns.

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.

In this video segment, Kircik described the data highlighted in his JAK inhibitor-related presentation at RAD 2025.

These data may upend the typically underperforming CETP inhibitor field with an accessible, oral medication for lowering LDL cholesterol.

This interview highlights the takeaways from Kircik’s talk at the 2025 RAD Conference regarding JAK inhibitor use and boxed warning concerns.

Compared to age-matched controls, women with premature menopause had greater risks of all-cause mortality and multiple cardiovascular complications.

Disrupted circadian rest-activity rhythms were tied to faster biological aging in older adults, independent of age, sex, or race, new study shows.

New data from a phase 2 and an OLE trial provide additional insight into the effects of iptacopan in IgA nephropathy.